TP-5801（Cat No.:I043384）is a novel, selective inhibitor of the protein tyrosine phosphatase 1B (PTP1B), an enzyme involved in regulating insulin signaling and glucose metabolism. By inhibiting PTP1B, TP-5801 aims to improve insulin sensitivity and reduce blood glucose levels, making it a potential therapeutic option for managing type 2 diabetes and obesity. In preclinical studies, TP-5801 has shown promise in enhancing insulin action and reducing hyperglycemia without causing significant side effects. Ongoing research is focused on evaluating its safety, efficacy, and potential for use in metabolic disease treatment.